Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial
- Resource Type
- article
- Source
- Nature Communications, Vol 12, Iss 1, Pp 1-11 (2021)
- Subject
Science - Language
- English
- ISSN
- 2041-1723